Parkinson's Disease - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 838
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P24C1120B3CEN
Leaflet:

Download PDF Leaflet

Parkinson's Disease - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Parkinson's Disease - Pipeline Review, H2 2015’, provides an overview of the Parkinson's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Parkinson's Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Parkinson's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Parkinson's Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Parkinson's Disease Overview
Therapeutics Development
Parkinson's Disease - Therapeutics under Development by Companies
Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes
Parkinson's Disease - Pipeline Products Glance
Parkinson's Disease - Products under Development by Companies
Parkinson's Disease - Products under Investigation by Universities/Institutes
Parkinson's Disease - Companies Involved in Therapeutics Development
Parkinson's Disease - Therapeutics Assessment
Drug Profiles
Parkinson's Disease - Recent Pipeline Updates
Parkinson's Disease - Dormant Projects
Parkinson's Disease - Discontinued Products
Parkinson's Disease - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Parkinson's Disease, H2 2015
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Parkinson's Disease - Pipeline by AC Immune SA, H2 2015
Parkinson's Disease - Pipeline by Acelot, Inc., H2 2015
Parkinson's Disease - Pipeline by Acorda Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2015
Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd., H2 2015
Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2015
Parkinson's Disease - Pipeline by Alexza Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Allergan Plc, H2 2015
Parkinson's Disease - Pipeline by Amabiotics SAS, H2 2015
Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
Parkinson's Disease - Pipeline by American Gene Technologies International Inc., H2 2015
Parkinson's Disease - Pipeline by Amicus Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by Anavex Life Sciences Corp., H2 2015
Parkinson's Disease - Pipeline by Angita B.V., H2 2015
Parkinson's Disease - Pipeline by Antoxis Limited, H2 2015
Parkinson's Disease - Pipeline by APeT Holding BV, H2 2015
Parkinson's Disease - Pipeline by Aposense Ltd., H2 2015
Parkinson's Disease - Pipeline by Araclon Biotech, S.L., H2 2015
Parkinson's Disease - Pipeline by ArmaGen,Inc., H2 2015
Parkinson's Disease - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Parkinson's Disease - Pipeline by Bial - Portela & Ca, S.A., H2 2015
Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H2 2015
Parkinson's Disease - Pipeline by BioArctic Neuroscience AB, H2 2015
Parkinson's Disease - Pipeline by Biogen, Inc., H2 2015
Parkinson's Disease - Pipeline by Bionature E.A. Ltd., H2 2015
Parkinson's Disease - Pipeline by Biopharm GmbH, H2 2015
Parkinson's Disease - Pipeline by Biotie Therapies Corp., H2 2015
Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015
Parkinson's Disease - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Calico LLC, H2 2015
Parkinson's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Cell Cure Neurosciences, Ltd., H2 2015
Parkinson's Disease - Pipeline by Cellceutix Corporation, H2 2015
Parkinson's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Parkinson's Disease - Pipeline by Chronos Therapeutics Limited, H2 2015
Parkinson's Disease - Pipeline by Clera Inc., H2 2015
Parkinson's Disease - Pipeline by Clevexel Pharma SAS, H2 2015
Parkinson's Disease - Pipeline by Contera Pharma ApS, H2 2015
Parkinson's Disease - Pipeline by Corium International, Inc., H2 2015
Parkinson's Disease - Pipeline by Curemark, LLC, H2 2015
Parkinson's Disease - Pipeline by Cynapsus Therapeutics Inc., H2 2015
Parkinson's Disease - Pipeline by D-Pharm Ltd., H2 2015
Parkinson's Disease - Pipeline by Depomed, Inc., H2 2015
Parkinson's Disease - Pipeline by DermaXon, LLC, H2 2015
Parkinson's Disease - Pipeline by Domain Therapeutics SA, H2 2015
Parkinson's Disease - Pipeline by Edison Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Eli Lilly and Company, H2 2015
Parkinson's Disease - Pipeline by Euroscreen S.A., H2 2015
Parkinson's Disease - Pipeline by Gardedam Therapeutics Inc., H2 2015
Parkinson's Disease - Pipeline by Gene Solutions LLC, H2 2015
Parkinson's Disease - Pipeline by Genecode AS, H2 2015
Parkinson's Disease - Pipeline by Genentech, Inc., H2 2015
Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
Parkinson's Disease - Pipeline by GenKyoTex S.A., H2 2015
Parkinson's Disease - Pipeline by Genosco, H2 2015
Parkinson's Disease - Pipeline by Genzyme Corporation, H2 2015
Parkinson's Disease - Pipeline by GliaCure Inc., H2 2015
Parkinson's Disease - Pipeline by H. Lundbeck A/S, H2 2015
Parkinson's Disease - Pipeline by Harbor Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by Heptares Therapeutics Limited, H2 2015
Parkinson's Disease - Pipeline by Herantis Pharma Plc, H2 2015
Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2015
Parkinson's Disease - Pipeline by Hua Medicine Ltd., H2 2015
Parkinson's Disease - Pipeline by Huons Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by Impel NeuroPharma, Inc., H2 2015
Parkinson's Disease - Pipeline by Intec Pharma ltd., H2 2015
Parkinson's Disease - Pipeline by Integrative Research Laboratories Sweden AB, H2 2015
Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H2 2015
Parkinson's Disease - Pipeline by International Stem Cell Corporation, H2 2015
Parkinson's Disease - Pipeline by Intra-Cellular Therapies, Inc., H2 2015
Parkinson's Disease - Pipeline by Io Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by Iproteos S.L., H2 2015
Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by KineMed, Inc., H2 2015
Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H2 2015
Parkinson's Disease - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Living Cell Technologies Limited, H2 2015
Parkinson's Disease - Pipeline by Longevity Biotech, Inc, H2 2015
Parkinson's Disease - Pipeline by Luye Pharma Group Ltd., H2 2015
Parkinson's Disease - Pipeline by M et P Pharma AG, H2 2015
Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc., H2 2015
Parkinson's Disease - Pipeline by Merck & Co., Inc., H2 2015
Parkinson's Disease - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015
Parkinson's Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2015
Parkinson's Disease - Pipeline by Minerva Neurosciences, Inc., H2 2015
Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H2 2015
Parkinson's Disease - Pipeline by MitoDys Therapeutics Limited, H2 2015
Parkinson's Disease - Pipeline by Motac Neuroscience Limited, H2 2015
Parkinson's Disease - Pipeline by Netherlands Translational Research Center B.V., H2 2015
Parkinson's Disease - Pipeline by Neuralstem, Inc., H2 2015
Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Limited, H2 2015
Parkinson's Disease - Pipeline by NeuroDerm Ltd., H2 2015
Parkinson's Disease - Pipeline by Neurodyn Inc., H2 2015
Parkinson's Disease - Pipeline by NeuroNascent, Inc., H2 2015
Parkinson's Disease - Pipeline by Neuronax SAS, H2 2015
Parkinson's Disease - Pipeline by NeurOp, Inc, H2 2015
Parkinson's Disease - Pipeline by Neuropore Therapies, Inc., H2 2015
Parkinson's Disease - Pipeline by New World Laboratories, Inc., H2 2015
Parkinson's Disease - Pipeline by Newron Pharmaceuticals S.p.A., H2 2015
Parkinson's Disease - Pipeline by nLife Therapeutics, S.L., H2 2015
Parkinson's Disease - Pipeline by Novartis AG, H2 2015
Parkinson's Disease - Pipeline by NsGene A/S, H2 2015
Parkinson's Disease - Pipeline by Omeros Corporation, H2 2015
Parkinson's Disease - Pipeline by Oncodesign SA, H2 2015
Parkinson's Disease - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by OPKO Health, Inc., H2 2015
Parkinson's Disease - Pipeline by Orion Oyj, H2 2015
Parkinson's Disease - Pipeline by Oryzon Genomics S.A., H2 2015
Parkinson's Disease - Pipeline by Osmotica Pharmaceutical Corp., H2 2015
Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H2 2015
Parkinson's Disease - Pipeline by Peptron, Inc., H2 2015
Parkinson's Disease - Pipeline by Pfizer Inc., H2 2015
Parkinson's Disease - Pipeline by Pharma Two B Ltd, H2 2015
Parkinson's Disease - Pipeline by PharmatrophiX, Inc., H2 2015
Parkinson's Disease - Pipeline by Pharmicell Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by Pharnext SAS, H2 2015
Parkinson's Disease - Pipeline by Prana Biotechnology Limited, H2 2015
Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H2 2015
Parkinson's Disease - Pipeline by Primary Peptides, Inc., H2 2015
Parkinson's Disease - Pipeline by Promentis Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Promius Pharma, LLC, H2 2015
Parkinson's Disease - Pipeline by Proteostasis Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by ProteoTech, Inc., H2 2015
Parkinson's Disease - Pipeline by Prothena Corporation Plc, H2 2015
Parkinson's Disease - Pipeline by QR Pharma, Inc., H2 2015
Parkinson's Disease - Pipeline by Raptor Pharmaceutical Corp., H2 2015
Parkinson's Disease - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2015
Parkinson's Disease - Pipeline by reMYND NV, H2 2015
Parkinson's Disease - Pipeline by RestorGenex Corporation, H2 2015
Parkinson's Disease - Pipeline by RhinoCyte, Inc., H2 2015
Parkinson's Disease - Pipeline by SanBio, Inc., H2 2015
Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by Saniona AB, H2 2015
Parkinson's Disease - Pipeline by Sellas Inc., H2 2015
Parkinson's Disease - Pipeline by Selvita SA, H2 2015
Parkinson's Disease - Pipeline by Serina Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by Shire Plc, H2 2015
Parkinson's Disease - Pipeline by Sigma-Tau S.p.A., H2 2015
Parkinson's Disease - Pipeline by SignPath Pharma Inc, H2 2015
Parkinson's Disease - Pipeline by Signum Biosciences, Inc., H2 2015
Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Parkinson's Disease - Pipeline by STATegics, Inc., H2 2015
Parkinson's Disease - Pipeline by Stelic Institute & Co., H2 2015
Parkinson's Disease - Pipeline by Synovo GmbH, H2 2015
Parkinson's Disease - Pipeline by Synthonics, Inc., H2 2015
Parkinson's Disease - Pipeline by Takara Bio Inc., H2 2015
Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd., H2 2015
Parkinson's Disease - Pipeline by Tautatis Incorporated, H2 2015
Parkinson's Disease - Pipeline by TechnoPhage SA, H2 2015
Parkinson's Disease - Pipeline by Teikoku Pharma USA, Inc., H2 2015
Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Parkinson's Disease - Pipeline by Titan Pharmaceuticals, Inc., H2 2015
Parkinson's Disease - Pipeline by Trevena, Inc., H2 2015
Parkinson's Disease - Pipeline by TyrNovo Ltd., H2 2015
Parkinson's Disease - Pipeline by UCB S.A., H2 2015
Parkinson's Disease - Pipeline by uniQure N.V., H2 2015
Parkinson's Disease - Pipeline by Varinel, Inc., H2 2015
Parkinson's Disease - Pipeline by Vernalis Plc, H2 2015
Parkinson's Disease - Pipeline by VistaGen Therapeutics , Inc., H2 2015
Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
Parkinson's Disease - Pipeline by Voyager Therapeutics, Inc., H2 2015
Parkinson's Disease - Pipeline by Wellstat Therapeutics Corporation, H2 2015
Parkinson's Disease - Pipeline by Zenobia Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Parkinson's Disease Therapeutics - Recent Pipeline Updates, H2 2015
Parkinson's Disease - Dormant Projects, H2 2015
Parkinson's Disease - Dormant Projects (Contd..1), H2 2015
Parkinson's Disease - Dormant Projects (Contd..2), H2 2015
Parkinson's Disease - Dormant Projects (Contd..3), H2 2015
Parkinson's Disease - Dormant Projects (Contd..4), H2 2015
Parkinson's Disease - Dormant Projects (Contd..5), H2 2015
Parkinson's Disease - Dormant Projects (Contd..6), H2 2015
Parkinson's Disease - Dormant Projects (Contd..7), H2 2015
Parkinson's Disease - Dormant Projects (Contd..8), H2 2015
Parkinson's Disease - Dormant Projects (Contd..9), H2 2015
Parkinson's Disease - Dormant Projects (Contd..10), H2 2015
Parkinson's Disease - Dormant Projects (Contd..11), H2 2015
Parkinson's Disease - Dormant Projects (Contd..12), H2 2015
Parkinson's Disease - Dormant Projects (Contd..13), H2 2015
Parkinson's Disease - Dormant Projects (Contd..14), H2 2015
Parkinson's Disease - Dormant Projects (Contd..15), H2 2015
Parkinson's Disease - Dormant Projects (Contd..16), H2 2015
Parkinson's Disease - Dormant Projects (Contd..17), H2 2015
Parkinson's Disease - Dormant Projects (Contd..18), H2 2015
Parkinson's Disease - Dormant Projects (Contd..19), H2 2015
Parkinson's Disease - Dormant Projects (Contd..20), H2 2015
Parkinson's Disease - Discontinued Products, H2 2015
Parkinson's Disease - Discontinued Products (Contd..1), H2 2015
Parkinson's Disease - Discontinued Products (Contd..2), H2 2015
Parkinson's Disease - Discontinued Products (Contd..3), H2 2015

LIST OF FIGURES

Number of Products under Development for Parkinson's Disease, H2 2015
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AC Immune SA
Acelot, Inc.
Acorda Therapeutics, Inc.
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Aeolus Pharmaceuticals, Inc.
AFFiRiS AG
Alexza Pharmaceuticals, Inc.
Allergan Plc
Amabiotics SAS
Amarantus Bioscience Holdings, Inc.
American Gene Technologies International Inc.
Amicus Therapeutics, Inc.
Anavex Life Sciences Corp.
Angita B.V.
Antoxis Limited
APeT Holding BV
Aposense Ltd.
Araclon Biotech, S.L.
ArmaGen,Inc.
Arrien Pharmaceuticals, LLC
Bial - Portela & Ca, S.A.
Bio-Modeling Systems SAS
BioArctic Neuroscience AB
Biogen, Inc.
Bionature E.A. Ltd.
Biopharm GmbH
Biotie Therapies Corp.
BrainStorm Cell Therapeutics Inc.
CalAsia Pharmaceuticals, Inc.
Calico LLC
Cardax Pharmaceuticals, Inc.
Cell Cure Neurosciences, Ltd.
Cellceutix Corporation
CHA Bio & Diostech Co., Ltd.
Chipscreen Biosciences Ltd
Chronos Therapeutics Limited
Clera Inc.
Clevexel Pharma SAS
Contera Pharma ApS
Corium International, Inc.
Curemark, LLC
Cynapsus Therapeutics Inc.
D-Pharm Ltd.
Depomed, Inc.
DermaXon, LLC
Domain Therapeutics SA
Edison Pharmaceuticals, Inc.
Eli Lilly and Company
Euroscreen S.A.
Gardedam Therapeutics Inc.
Gene Solutions LLC
Genecode AS
Genentech, Inc.
Genervon Biopharmaceuticals, LLC
GenKyoTex S.A.
Genosco
Genzyme Corporation
GliaCure Inc.
H. Lundbeck A/S
Harbor Therapeutics, Inc.
Heptares Therapeutics Limited
Herantis Pharma Plc
Hisamitsu Pharmaceutical Co., Inc.
Hua Medicine Ltd.
Huons Co., Ltd.
Impel NeuroPharma, Inc.
Intec Pharma ltd.
Integrative Research Laboratories Sweden AB
InterMed Discovery GmbH
International Stem Cell Corporation
Intra-Cellular Therapies, Inc.
Io Therapeutics, Inc.
Iproteos S.L.
Jeil Pharmaceutical Co., Ltd.
KineMed, Inc.
Kissei Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
Lead Discovery Center GmbH
Ligand Pharmaceuticals, Inc.
Living Cell Technologies Limited
Longevity Biotech, Inc
Luye Pharma Group Ltd.
M et P Pharma AG
MedGenesis Therapeutix Inc.
Merck & Co., Inc.
Merz Pharma GmbH & Co. KgaA
Metabolic Solutions Development Company, LLC
Minerva Neurosciences, Inc.
Mission Therapeutics Ltd
MitoDys Therapeutics Limited
Motac Neuroscience Limited
Netherlands Translational Research Center B.V.
Neuralstem, Inc.
Neuraltus Pharmaceuticals, Inc.
Neuren Pharmaceuticals Limited
NeuroDerm Ltd.
Neurodyn Inc.
NeuroNascent, Inc.
Neuronax SAS
NeurOp, Inc
Neuropore Therapies, Inc.
New World Laboratories, Inc.
Newron Pharmaceuticals S.p.A.
nLife Therapeutics, S.L.
Novartis AG
NsGene A/S
Omeros Corporation
Oncodesign SA
Ono Pharmaceutical Co., Ltd.
OPKO Health, Inc.
Orion Oyj
Oryzon Genomics S.A.
Osmotica Pharmaceutical Corp.
Oxford BioMedica Plc
Peptron, Inc.
Pfizer Inc.
Pharma Two B Ltd
PharmatrophiX, Inc.
Pharmicell Co., Ltd.
Pharnext SAS
Prana Biotechnology Limited
Prexton Therapeutics SA
Primary Peptides, Inc.
Promentis Pharmaceuticals, Inc.
Promius Pharma, LLC
Proteostasis Therapeutics, Inc.
ProteoTech, Inc.
Prothena Corporation Plc
QR Pharma, Inc.
Raptor Pharmaceutical Corp.
Reliance Life Sciences Pvt. Ltd.
reMYND NV
RestorGenex Corporation
RhinoCyte, Inc.
SanBio, Inc.
Saneron CCEL Therapeutics, Inc.
Saniona AB
Sellas Inc.
Selvita SA
Serina Therapeutics, Inc.
Shire Plc
Sigma-Tau S.p.A.
SignPath Pharma Inc
Signum Biosciences, Inc.
SK Biopharmaceuticals Co., Ltd.
STATegics, Inc.
Stelic Institute & Co.
Synovo GmbH
Synthonics, Inc.
Takara Bio Inc.
Takeda Pharmaceutical Company Limited
TauRx Therapeutics Ltd.
Tautatis Incorporated
TechnoPhage SA
Teikoku Pharma USA, Inc.
Teva Pharmaceutical Industries Limited
Titan Pharmaceuticals, Inc.
Trevena, Inc.
TyrNovo Ltd.
UCB S.A.
uniQure N.V.
Varinel, Inc.
Vernalis Plc
VistaGen Therapeutics , Inc.
VivaCell Biotechnology Espana S.L.
Voyager Therapeutics, Inc.
Wellstat Therapeutics Corporation
Zenobia Therapeutics, Inc.
Skip to top


Charcot-Marie-Tooth Disease - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 56 pages
Degenerative Disc Disease - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 80 pages
Gaucher Disease - Pipeline Review, H1 2016 US$ 2,000.00 Jun, 2016 · 78 pages
Raynauds Disease - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 62 pages

Ask Your Question

Parkinson's Disease - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: